Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-08-08 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于杭州安杰思医学科技股份有限公司部分募投项目延期的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the delay of certain fundraising investment projects by Hangzhou Anjiesi Medical Technology Co., Ltd. It includes specifics about the fundraising amount, usage progress, reasons for project delays, necessity and feasibility analysis, impact on the company, and the approval procedures by the board and supervisory committee. The document references regulatory guidelines and confirms compliance with fundraising management rules. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a formal audit or verification report related to fundraising project delays, which fits the category of an Audit Report / Information (AR). The document length is 4084 characters, which is substantial and contains detailed substantive content, not just an announcement or certification. Therefore, the best classification is AR with high confidence. H1 2024
2024-08-08 Chinese
安杰思关于向2023年限制性股票激励计划激励对象授予预留部分限制性股票的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the reserved grant of restricted stock under the 2023 restricted stock incentive plan. It details the number of shares, grant price, conditions, approval procedures, and legal opinions related to the stock incentive plan. The content focuses on the company's equity incentive plan, including board and supervisory committee approvals, legal compliance, and accounting treatment of the stock grant. This type of document is a formal announcement about a capital change related to share issuance under an incentive plan, rather than a full financial report or management discussion. It does not contain financial statements or earnings data but rather details about share grants and related approvals. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is sufficient and detailed, not a mere announcement of a report publication or a regulatory filing. Hence, the classification is SHA with high confidence.
2024-08-08 Chinese
中信证券股份有限公司关于杭州安杰思医学科技股份有限公司使用部分超募资金永久补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsor (中信证券股份有限公司) regarding the use of part of the over-raised funds by 杭州安杰思医学科技股份有限公司 to permanently supplement working capital. It references regulatory guidelines related to the management and use of raised funds, details the amount of funds raised, the intended use of funds, and the approval process including board and supervisory committee meetings. The document is not a full financial report but rather a regulatory compliance and verification statement related to capital use. It does not contain financial statements or earnings data, nor is it a brief announcement or a proxy statement. It is a regulatory filing related to capital use and compliance with securities regulations, fitting best under the category of Regulatory Filings (RNS). The document length is 2680 characters, which is relatively short and consistent with a regulatory compliance filing rather than a full report.
2024-08-08 Chinese
安杰思关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, the price range, the total amount spent, and references previous announcements about the share repurchase plan. It does not contain financial statements or detailed financial analysis but is a regulatory update on the company's share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buying back or selling its own shares.
2024-08-01 Chinese
安杰思关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, the price range, the total amount spent, and references previous announcements about the share buyback plan. It does not contain financial statements or detailed financial analysis but is a regulatory update on the company's share repurchase activity. This fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back its own shares.
2024-07-03 Chinese
安杰思关于投资建设杭安医学科技（杭州）有限公司高端诊疗设备项目的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Hangzhou Anjiesi Medical Technology Co., Ltd. regarding an investment project to build a high-end diagnostic equipment facility through its wholly-owned subsidiary. It details the investment amount, funding source, project location, construction timeline, and associated risks. The document is a formal disclosure of a capital investment decision by the company's board, including risk factors and strategic rationale. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a report or financial statement but an announcement of a capital expenditure project. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including significant investment projects.
2024-06-28 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.